Novavax has developed a platform upon which we can manufacture a variety of proprietary recombinant nanoparticle vaccines.
Novavax’ clinical pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease.
Mervyn L. Hamer
